EDMONTON, Alberta, Dec. 6, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) (“Isotechnika” or the “Company”) is pleased to announce positive anti-hepatitis C virus (“HCV”) results from the second round of in vitro testing of its cyclophilin antagonist molecules (“NICAMs”). Contractors funded by the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the U.S. National Institutes of Health (“NIH”), carried out the testing.
